Summit Therapeutics Inc.
ivonescimab
non-small cell lung cancer (NSCLC)
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on ivonescimab for non-small cell lung cancer (NSCLC) is in focus around Date TBD.
Primary source
· SEC 8-K
verified 16h ago
“the FDA provided a Prescription Drug User Fee Act (PDUFA) goal action date of November 14, 2026.”